u-Agasti21,I-bispecific T cell engager, i-epcoritamab, inikezwe ukubuyekezwa okubalulekile yi-Center for Drug Evaluation (CDE) ye-National Medical Products Administration (NMPA). Ukuvunyelwa kuqondiswe ezigulini ezindala ezine-relapse or refractory follicular lymphoma (FL), okuyisigaba esidingekayo kakhulu se-B cell mognancies.
Njengamanje, kusenezivivinyo eziningi zemitholampilo zobuchwepheshe obusha bokulwa nomdlavuza eShayina ezifuna iziguli. Ukubonisana ngemithi emisha kanye nobuchwepheshe, ungaxhumana noMnyango Wezizwe Ngezizwe Wesibhedlela iBeijing South Region Oncology.
Inombolo yocingo: 4008803716
I-ID ye-WeChat: 17801183037
Email：myimmnet@163.com
Mayelana ne-Epcoritamab
I-Epcoritamab iyi-antibody ye-IgG1-bispecific eyakhiwe kusetshenziswa ubuchwepheshe be-DuoBody obukhethekile be-Genmab futhi iphathwa ngaphansi kwesikhumba. Ubuchwepheshe be-DuoBody-CD3 be-Genmab buklanyelwe ukuqondisa amaseli e-T anobuthi ngokukhetha ukuze kutholakale impendulo yokuzivikela ezinhlotsheni zamaseli aqondiwe. I-Epcoritamab iklanyelwe ukubopha ngasikhathi sinye kumaseli e-T kanye namaseli e-CD20 kanye namaseli e-B futhi ibangele ukubulawa kwamaseli e-CD20+ okubangelwa amaseli e-T.
Mayelana ne-Follicular Lymphoma (FL)
I-FL ngokuvamile uhlobo oluhlala luvilapha (noma olukhula kancane) lwe-non-Hodgkin's lymphoma (NHL) oluvela kuma-B-lymphocytes futhi uhlobo lwesibili oluvame kakhulu lwe-NHL olubala amaphesenti angama-20-30 azo zonke izimo. Abantu ababalelwa ku-15,000 bahlakulela i-FL minyaka yonke e-USii futhi kubhekwa njengokungalapheki ngemithi yokwelapha ejwayelekile yokunakekelwa. iii Iziguli zivame ukubuyela emuva futhi, ngokubuyela emuva ngakunye, ukuxolelwa nesikhathi sokwelashwa okulandelayo kuba mfushane. iv Ngokuhamba kwesikhathi, ukuguqulwa kube ukusabalalisa i-large B-cell lymphoma (DLBCL), uhlobo olunamandla lwe-NHL oluhambisana nemiphumela emibi yokusinda, kungenzeka kubantu abangaphezu kwamaphesenti angama-25 be-FL.
I-EPCORE FL-1 (I-NCT05409066) luyisilingo sokungenelela seSigaba sesi-3 esivulekile sokuhlola ukuphepha nokusebenza kahle kwe-epcoritamab kanye ne-rituximab kanye ne-lenalidomide (R2) uma kuqhathaniswa ne-R2 yodwa ezigulini ezine-relapse/refractory (R/R) follicular lymphoma (FL).
7 Agasti,I-Genmab A/Simemezele imiphumela emihle yesivivinyo seSigaba sesi-3 se-EPCORE FL-1 esihlola i-epcoritamab engaphansi kwesikhumba, i-antibody ye-bispecific, ehlanganiswe ne-rituximab kanye ne-lenalidomide (R®2) uma kuqhathaniswa ne-R2 yodwa yokwelapha iziguli ezindala ezine-relapse or refractory (R/R) follicular lymphoma (FL). Ucwaningo luhlangabezane nezindawo zalo ezimbili eziyinhloko zesilinganiso sokuphendula jikelele (ORR, p-value <0.0001) kanye nokusinda okungenazo inqubekela phambili (PFS, HR 0.21, p-value <0.0001), okubonisa umehluko obalulekile ngokwezibalo kanye nowengqondo kuzo zombili izindawo zokugcina, kunciphisa ingozi yokuqhubeka kwesifo noma ukufa ngo-79%.
Njengamanje, kusenezivivinyo eziningi zemitholampilo zobuchwepheshe obusha bokulwa nomdlavuza eShayina ezifuna iziguli. Ukubonisana ngemithi emisha kanye nobuchwepheshe, ungaxhumana noMnyango Wezizwe Ngezizwe Wesibhedlela iBeijing South Region Oncology.
Inombolo yocingo: 4008803716
I-ID ye-WeChat: 17801183037
Email：myimmnet@163.com
Isikhathi sokuthunyelwe: Septhemba-05-2025